Vetter breaks ground on manufacturing facility in Germany
Scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Expected to cost approximately 70 million euro ($79 million),
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform.
The novel compounds, developed in the laboratory of Harvard scientist Matthew Shair, Ph.D., offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription. Acute myeloid leukemia